Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.59
WAT's Cash-to-Debt is ranked lower than
51% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. WAT: 1.59 )
Ranked among companies with meaningful Cash-to-Debt only.
WAT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.03 Max: N/A
Current: 1.59
Equity-to-Asset 0.50
WAT's Equity-to-Asset is ranked lower than
67% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. WAT: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
WAT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.05  Med: 0.45 Max: 0.7
Current: 0.5
-0.05
0.7
Interest Coverage 13.27
WAT's Interest Coverage is ranked lower than
67% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. WAT: 13.27 )
Ranked among companies with meaningful Interest Coverage only.
WAT' s Interest Coverage Range Over the Past 10 Years
Min: 6.17  Med: 16.44 Max: 35.92
Current: 13.27
6.17
35.92
Piotroski F-Score: 7
Altman Z-Score: 6.83
Beneish M-Score: -2.58
WACC vs ROIC
8.82%
42.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 28.79
WAT's Operating Margin % is ranked higher than
95% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. WAT: 28.79 )
Ranked among companies with meaningful Operating Margin % only.
WAT' s Operating Margin % Range Over the Past 10 Years
Min: 23.68  Med: 27.28 Max: 28.81
Current: 28.79
23.68
28.81
Net Margin % 24.34
WAT's Net Margin % is ranked higher than
94% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. WAT: 24.34 )
Ranked among companies with meaningful Net Margin % only.
WAT' s Net Margin % Range Over the Past 10 Years
Min: 18.2  Med: 23.1 Max: 25.03
Current: 24.34
18.2
25.03
ROE % 23.78
WAT's ROE % is ranked higher than
93% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. WAT: 23.78 )
Ranked among companies with meaningful ROE % only.
WAT' s ROE % Range Over the Past 10 Years
Min: 23.6  Med: 36 Max: 56.53
Current: 23.78
23.6
56.53
ROA % 11.66
WAT's ROA % is ranked higher than
87% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. WAT: 11.66 )
Ranked among companies with meaningful ROA % only.
WAT' s ROA % Range Over the Past 10 Years
Min: 11.52  Med: 15.5 Max: 18.41
Current: 11.66
11.52
18.41
ROC (Joel Greenblatt) % 87.42
WAT's ROC (Joel Greenblatt) % is ranked higher than
94% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. WAT: 87.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WAT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 72.34  Med: 85.19 Max: 96.98
Current: 87.42
72.34
96.98
3-Year Revenue Growth Rate 6.60
WAT's 3-Year Revenue Growth Rate is ranked higher than
59% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. WAT: 6.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WAT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.2  Med: 8.9 Max: 19.5
Current: 6.6
5.2
19.5
3-Year EBITDA Growth Rate 9.50
WAT's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. WAT: 9.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WAT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 2.4  Med: 11 Max: 69.2
Current: 9.5
2.4
69.2
3-Year EPS without NRI Growth Rate 7.20
WAT's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. WAT: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WAT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 2.6  Med: 14.6 Max: 79.9
Current: 7.2
2.6
79.9
GuruFocus has detected 3 Warning Signs with Waters Corp $WAT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WAT's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

WAT Guru Trades in Q2 2016

Ray Dalio 2,600 sh (New)
Pioneer Investments 8,690 sh (New)
Louis Moore Bacon 18,000 sh (New)
Paul Tudor Jones 2,800 sh (New)
Joel Greenblatt 105,556 sh (+338.25%)
Jeremy Grantham Sold Out
Jim Simons Sold Out
PRIMECAP Management 628,667 sh (-3.41%)
Ruane Cunniff 1,770,014 sh (-7.85%)
Chuck Royce 5,047 sh (-55.68%)
» More
Q3 2016

WAT Guru Trades in Q3 2016

Jim Simons 20,200 sh (New)
Paul Tudor Jones 3,900 sh (+39.29%)
Ruane Cunniff 1,777,909 sh (+0.45%)
Chuck Royce 5,047 sh (unchged)
Pioneer Investments 8,690 sh (unchged)
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
PRIMECAP Management 488,487 sh (-22.30%)
Joel Greenblatt 41,642 sh (-60.55%)
» More
Q4 2016

WAT Guru Trades in Q4 2016

Jim Simons 195,300 sh (+866.83%)
Joel Greenblatt 56,708 sh (+36.18%)
Paul Tudor Jones 4,190 sh (+7.44%)
Pioneer Investments 8,690 sh (unchged)
Chuck Royce Sold Out
Ruane Cunniff 1,718,469 sh (-3.34%)
PRIMECAP Management 471,657 sh (-3.45%)
» More
Q1 2017

WAT Guru Trades in Q1 2017

Pioneer Investments Sold Out
Ruane Cunniff 1,669,196 sh (-2.87%)
PRIMECAP Management 436,137 sh (-7.53%)
Jim Simons 167,400 sh (-14.29%)
Joel Greenblatt 40,730 sh (-28.18%)
Paul Tudor Jones 1,700 sh (-59.43%)
» More
» Details

Insider Trades

Latest Guru Trades with WAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:XRAY, OTCPK:TRUMF, NYSE:MTD, OTCPK:OCPNY, NAS:HOLX, NYSE:COO, OTCPK:CLPBY, NYSE:RMD, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:BCR, OTCPK:GNGBF, NYSE:HRC, NYSE:CMD, NAS:ICUI, NAS:ILMN, OTCPK:ANSLF, NAS:PODD, NYSE:HAE » details
Traded in other countries:WAZ.Germany,
Headquarter Location:USA
Waters Corp is an analytical instrument manufacturer. It designs, manufactures, sells and services liquid chromatography, ultra performance liquid chromatography & mass spectrometry instrument systems & support products.

Waters provides analytical instruments for pharmaceutical, biochemical, and industrial customers. Roughly half of sales are attributable to instruments, which include liquid chromatography and mass spectrometry platforms, as well as thermal analysis tools. Consumables and services account for the remainder of Waters' sales.

Top Ranked Articles about Waters Corp

What Does 'Understanding' a Business Really Mean? It means understanding the economics that drive customer and competitor decision making
Someone who reads my blog emailed me this question: Read more...
Weekly CFO Sells Highlights Insiders trade Facebook, Waters and Cerner
According to GuruFocus Insider Data, the recent CFO sells were: Facebook Inc. (NASDAQ:FB), Waters Corp. (NYSE:WAT) and Cerner Corp. (NASDAQ:CERN). Read more...
Eugene Cassis Sells Waters Corp. CFO sold shares of the company
Eugene Cassis (Insider Trades), CFO of Waters Corp. (WAT), sold 48,000 shares of the company on Aug. 1. The average price per share was $159.96, for a total transaction of $7,678,080. Read more...

Ratios

vs
industry
vs
history
PE Ratio 27.14
WAT's PE Ratio is ranked higher than
64% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. WAT: 27.14 )
Ranked among companies with meaningful PE Ratio only.
WAT' s PE Ratio Range Over the Past 10 Years
Min: 9.64  Med: 20.93 Max: 32.25
Current: 27.14
9.64
32.25
Forward PE Ratio 25.25
WAT's Forward PE Ratio is ranked higher than
55% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. WAT: 25.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.14
WAT's PE Ratio without NRI is ranked higher than
64% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. WAT: 27.14 )
Ranked among companies with meaningful PE Ratio without NRI only.
WAT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.64  Med: 20.93 Max: 32.25
Current: 27.14
9.64
32.25
Price-to-Owner-Earnings 27.68
WAT's Price-to-Owner-Earnings is ranked higher than
60% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. WAT: 27.68 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.12  Med: 22.75 Max: 34.46
Current: 27.68
10.12
34.46
PB Ratio 5.95
WAT's PB Ratio is ranked lower than
71% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. WAT: 5.95 )
Ranked among companies with meaningful PB Ratio only.
WAT' s PB Ratio Range Over the Past 10 Years
Min: 4.38  Med: 5.8 Max: 19.91
Current: 5.95
4.38
19.91
PS Ratio 6.60
WAT's PS Ratio is ranked lower than
73% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. WAT: 6.60 )
Ranked among companies with meaningful PS Ratio only.
WAT' s PS Ratio Range Over the Past 10 Years
Min: 2.05  Med: 4.51 Max: 6.62
Current: 6.6
2.05
6.62
Price-to-Free-Cash-Flow 26.08
WAT's Price-to-Free-Cash-Flow is ranked higher than
63% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. WAT: 26.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.66  Med: 22.16 Max: 30.04
Current: 26.08
9.66
30.04
Price-to-Operating-Cash-Flow 22.51
WAT's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. WAT: 22.51 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.82  Med: 17.84 Max: 24.68
Current: 22.51
7.82
24.68
EV-to-EBIT 20.10
WAT's EV-to-EBIT is ranked higher than
69% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. WAT: 20.10 )
Ranked among companies with meaningful EV-to-EBIT only.
WAT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 16.3 Max: 23.6
Current: 20.1
8.1
23.6
EV-to-EBITDA 17.53
WAT's EV-to-EBITDA is ranked higher than
62% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. WAT: 17.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
WAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7  Med: 14.2 Max: 20.6
Current: 17.53
7
20.6
PEG Ratio 3.87
WAT's PEG Ratio is ranked lower than
62% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. WAT: 3.87 )
Ranked among companies with meaningful PEG Ratio only.
WAT' s PEG Ratio Range Over the Past 10 Years
Min: 0.58  Med: 1.66 Max: 4.36
Current: 3.87
0.58
4.36
Shiller PE Ratio 36.18
WAT's Shiller PE Ratio is ranked higher than
69% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. WAT: 36.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
WAT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.64  Med: 30.07 Max: 51.34
Current: 36.18
16.64
51.34
Current Ratio 5.98
WAT's Current Ratio is ranked higher than
89% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. WAT: 5.98 )
Ranked among companies with meaningful Current Ratio only.
WAT' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.89 Max: 6.99
Current: 5.98
1.19
6.99
Quick Ratio 5.53
WAT's Quick Ratio is ranked higher than
90% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. WAT: 5.53 )
Ranked among companies with meaningful Quick Ratio only.
WAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.51 Max: 6.48
Current: 5.53
0.74
6.48
Days Inventory 114.95
WAT's Days Inventory is ranked higher than
57% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. WAT: 114.95 )
Ranked among companies with meaningful Days Inventory only.
WAT' s Days Inventory Range Over the Past 10 Years
Min: 96.3  Med: 107.8 Max: 114.95
Current: 114.95
96.3
114.95
Days Sales Outstanding 76.95
WAT's Days Sales Outstanding is ranked lower than
75% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. WAT: 76.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
WAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.61  Med: 79.57 Max: 83.7
Current: 76.95
67.61
83.7
Days Payable 27.10
WAT's Days Payable is ranked lower than
84% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. WAT: 27.10 )
Ranked among companies with meaningful Days Payable only.
WAT' s Days Payable Range Over the Past 10 Years
Min: 26.08  Med: 28.41 Max: 35.98
Current: 27.1
26.08
35.98

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.10
WAT's 5-Year Yield-on-Cost % is ranked lower than
96% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. WAT: 0.10 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WAT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.1
3-Year Average Share Buyback Ratio 1.90
WAT's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. WAT: 1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 2.4 Max: 6.3
Current: 1.9
-3.1
6.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 25.88
WAT's Price-to-Net-Cash is ranked lower than
71% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. WAT: 25.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
WAT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 22.72  Med: 60.93 Max: 401.52
Current: 25.88
22.72
401.52
Price-to-Net-Current-Asset-Value 10.47
WAT's Price-to-Net-Current-Asset-Value is ranked lower than
59% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. WAT: 10.47 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WAT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.43  Med: 16.24 Max: 310.33
Current: 10.47
8.43
310.33
Price-to-Tangible-Book 7.79
WAT's Price-to-Tangible-Book is ranked lower than
66% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. WAT: 7.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WAT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.17  Med: 11.88 Max: 1545.29
Current: 7.79
6.17
1545.29
Price-to-Intrinsic-Value-Projected-FCF 2.15
WAT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. WAT: 2.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WAT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.65 Max: 10.23
Current: 2.15
0.87
10.23
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.77
WAT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
65% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. WAT: 1.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.46
WAT's Price-to-Median-PS-Value is ranked lower than
59% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. WAT: 1.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 0.97 Max: 3.44
Current: 1.46
0.28
3.44
Price-to-Peter-Lynch-Fair-Value 3.59
WAT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.21 vs. WAT: 3.59 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WAT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.66  Med: 1.69 Max: 5.81
Current: 3.59
0.66
5.81
Price-to-Graham-Number 3.07
WAT's Price-to-Graham-Number is ranked lower than
55% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. WAT: 3.07 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WAT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.34  Med: 3.34 Max: 49.57
Current: 3.07
2.34
49.57
Earnings Yield (Greenblatt) % 4.98
WAT's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. WAT: 4.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.2  Med: 6.1 Max: 12.4
Current: 4.98
4.2
12.4
Forward Rate of Return (Yacktman) % 10.44
WAT's Forward Rate of Return (Yacktman) % is ranked higher than
51% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. WAT: 10.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WAT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.1  Med: 15.3 Max: 26.6
Current: 10.44
9.1
26.6

More Statistics

Revenue (TTM) (Mil) $2,190
EPS (TTM) $ 6.56
Beta1.23
Short Percentage of Float3.13%
52-Week Range $131.35 - 179.07
Shares Outstanding (Mil)80.04

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,253 2,377 2,524
EPS ($) 7.08 7.56 8.48
EPS without NRI ($) 7.08 7.56 8.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.67%
Dividends per Share ($)
» More Articles for WAT

Headlines

Articles On GuruFocus.com
Just Buy It Mar 27 2017 
What Does 'Understanding' a Business Really Mean? Nov 30 2016 
Weekly CFO Sells Highlights Aug 23 2016 
Eugene Cassis Sells Waters Corp. Aug 02 2016 
Companies Hit 52-Week Highs Jul 19 2016 
My Favorite Health Care Stocks Jul 12 2016 
5 Companies Hit Their 52-Week Highs May 31 2016 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Weekly Insider Sells Highlights: Walgreens Boots Alliance, Waters, Fitbit, Extra Space Storage Nov 24 2015 
Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MAS Dec 14 2014 

More From Other Websites
Waters Corp. Rides High on Thriving Pharmaceutical Business May 26 2017
How Waters Corporation (WAT) Stock Stands Out in a Strong Industry May 26 2017
Waters Corp (WAT) Up 3.9% Since Earnings Report: Can It Continue? May 26 2017
Oil Down, Everything Else Up on the Day May 25 2017
Top Ranked Momentum Stocks to Buy for May 16th May 16 2017
Edited Transcript of WAT earnings conference call or presentation 25-Apr-17 12:00pm GMT Apr 27 2017
Waters CEO on earnings Apr 25 2017
Waters Corp. (WAT) Q1 Earnings Beat, Organic Growth Strong Apr 25 2017
Waters Corp. (WAT) Q1 Earnings and Revenues Beat Estimates Apr 25 2017
Waters beats Street 1Q forecasts Apr 25 2017
Waters Corporation (NYSE: WAT) Reports First Quarter 2017 Financial Results Apr 25 2017
What's in the Cards for Waters Corp. (WAT) in Q1 Earnings? Apr 20 2017
VICAM Introduces New Rapid, Solvent-free Method for Ochratoxin A Detection in Coffee and Wheat Apr 19 2017
Caledonia Investments Plc Buys Waters, Watsco Apr 13 2017
Waters Corporation Q1 2017 Financial Results Webcast Invitation Apr 06 2017
Waters Corp (WAT) Poised to Grow on Positive Industry Trends Mar 29 2017
Waters Corp. Boosts Progenesis QI Software with Proteolabels Mar 16 2017
Waters Now Offers Proteolabels Software Mar 15 2017
[$$] Funding Snapshot: RedShift Raises $11 Million Series C for Protein Therapeutic Drugs Mar 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)